Xcout IntelPLUS THERAPEUTICS, Inc.
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Subscribe to see PLUS THERAPEUTICS, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
PLUS THERAPEUTICS, Inc. at a glance
PLUS THERAPEUTICS, Inc. is a biotech company headquartered in Austin, United States, founded in 1996. It is publicly listed (PSTV) with a market capitalisation of $9M. Xcout tracks 14 named people at PLUS THERAPEUTICS, Inc., including Marc H. Hedrick (President, Chief Executive Officer & Director).
PLUS THERAPEUTICS, Inc. leadership
- Marc H. HedrickPresident, Chief Executive Officer & Director
- Russell W. BradleyPresident & GM of CNSide Diagnostics, LLC
- Andrew J. SimsVice President & Chief Financial Officer
- Eric J. DanielsChief Development Officer
- Russ HavranekExecutive Vice President of Commercial and Corporate Strategy
- Desiree SmithCorporate Controller
8 more named people on record for PLUS THERAPEUTICS, Inc., with roles, board committees and tenure — see the full roster →
Investors
PLUS THERAPEUTICS, Inc. competitors
A few of PLUS THERAPEUTICS, Inc.'s closest competitors — see the full list of competitors and alternatives →
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Neotx Holdings Ltd. is a biopharmaceutical company that develops cancer therapeutics and immunotherapies. It conducts clinical trials and researches proprietary technologies aimed at advancing cancer treatment.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Ollin Biosciences is a clinical-stage biopharmaceutical holding company established in 2023 and headquartered in Austin, Texas, dedicated to developing therapeutics.
Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.
Get PLUS THERAPEUTICS, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on PLUS THERAPEUTICS, Inc. in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access